Action TCON TRACON PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues TRACON Pharmaceuticals, Inc.

Actions

TCON

US89237H3084

Marché Fermé - OTC Markets
Autres places de cotation
 21:57:51 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,6222 USD -20,23 % Graphique intraday de TRACON Pharmaceuticals, Inc. -18,66 % -82,23 %
01/07 TRACON Pharmaceuticals explore des alternatives stratégiques en s'appuyant sur sa plateforme interne de développement de produits CI
01/07 Mise à jour sectorielle : Les actions du secteur de la santé en baisse dans l'après-midi MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index
TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Sector Update: Health Care
Tracon to Explore Strategic Alternatives After Trial Misses Target
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform
TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index
TRACON Pharmaceuticals, Inc. Announces Resignation of David Lazar as Chief Business Development Officer
Top Premarket Decliners
TRACON Pharmaceuticals : Failure to Satisfy Listing Rule Form 8 K
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tracon: Q1 Earnings Snapshot
Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Tracon Pharmaceuticals, Inc. Appoints David Lazar as Chief Business Development Officer
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
TRACON Pharmaceuticals Announces Reverse Stock Split
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TCON
  4. Actualités TRACON Pharmaceuticals, Inc.
  5. Autres langues